Focus: PharmaIN is a Bothell-based biotech company focused on subcutaneous peptide formulations and out-licensing strategies across multiple therapeutic areas. The company generates meaningful revenue from a diversified generic and branded portfolio, anchored by lidocaine products.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow PharmaIN to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generates 35% of company revenue as a mature generic with no patent cliff date listed; core profit driver facing ongoing generic erosion.
Help build intelligence for PharmaIN
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from PharmaIN's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Premium branded lidocaine formulation at peak sales with LOE cliff not until 2031; key revenue defender for next 6+ years.
NDA-derived diuretic at peak with late patent cliff (2033); stable but modest contributor.
Generic dermatology product in post-LOE phase facing ongoing price and volume pressure.
Generic aromatase inhibitor in post-LOE; mature oncology product with limited growth.
798 discontinued, 359 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub
No disclosed warn notices or FDA warnings; however, 2 active drug shortages (amphetamine and technetium products) indicate supply chain fragility that could distract management and reduce hiring.
+227 more products